Breaking Down Mani, Inc. Financial Health: Key Insights for Investors

Mani, Inc.'s latest results demand attention: fiscal-year net sales rose to ¥29,968 million (+5.1%) led by Surgical and Eyeless Needle strength even as the Dental segment was hit by a March 2025 China recall that shaved ¥1,481 million from sales and ¥1,192 million from profit; gross profit reached ¥19,318 million with a 64.5% gross margin while operating income slipped to ¥8,193 million (27.3% margin) and net income fell to ¥5,167 million, leaving EPS at ¥47.14 and a trailing P/E of 30.15; balance-sheet metrics show a conservative capital structure with net cash of ¥17.41 billion, a debt-to-equity of 0.14%, current ratio 8.17 and interest coverage ~1,400x, and management projects 9.4% revenue growth for FY2026 as Dental recovery in China, U.S. expansion, JIZAI product scaling and ¥2.8 billion planned R&D investment drive the outlook-read on for a granular breakdown of liquidity, valuation (P/S 4.67, P/B 2.58, forward P/E 21.17), risks including a ¥1,190 million impairment at MMG and regional/regulatory exposures, and what these figures mean for investors assessing Mani's financial health.

Mani, Inc. (7730.T) - Revenue Analysis

For the fiscal year ending August 31, 2025, Mani, Inc. (7730.T) reported net sales of ¥29,968 million, a 5.1% increase year-over-year. Growth was driven largely by the Surgical and Eyeless Needle segments, while the Dental segment declined due to a voluntary product recall in China and underperformance in Europe.

• Net sales (FY 2025): ¥29,968 million (+5.1% YoY)
• Recall-related sales reduction (China, initiated March 2025): ¥1,481 million
• Recall-related profit impact: ¥1,192 million
• Projected revenue growth (FY 2026): 9.4% (assumes Dental recovery, resumption of China sales)
• Revenue per employee: ≈ ¥7.24 million

Projected FY 2026 net sales derived from FY 2025 base (¥29,968M × 1.094 ≈ ¥32,777M).

Further context on Mani's business model and corporate background is available here: Mani, Inc.: History, Ownership, Mission, How It Works & Makes Money

Mani, Inc. (7730.T) - Profitability Metrics

• Gross profit (FY2025): ¥19,318 million; gross margin: 64.5% (up from 62.8% in FY2024).
• Operating income (FY2025): ¥8,193 million, down 2.4% from FY2024; operating margin: 27.3% (FY2024: 29.4%).
• Net income (FY2025): ¥5,167 million, down 17.8% from FY2024 - impacted by the China recall and an MMG impairment.
• Earnings per share (TTM): ¥47.14; P/E ratio: 30.15.
• Return on equity (ROE): 9.71%; return on assets (ROA): 8.85%.
• Net profit margin (FY2025): 22.05% - indicating a solid conversion of revenue into profit despite one-off headwinds.

• Investors should note the combination of expanding gross margin and contracting operating/net margins - signaling margin pressure below gross profit (operating disruptions and one-time charges).
• Valuation context: with EPS ¥47.14 and a P/E of 30.15, the market is pricing future growth; compare this with peers and Mani's historical multiples before forming an investment view.

Mani, Inc. (7730.T) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.14%
• Net cash position: ¥17.41 billion
• Cash and marketable securities: ¥17.49 billion
• Total debt: ¥76 million
• Interest coverage ratio: ~1,400×
• Current ratio: 8.17
• Quick ratio: 6.54
• Net debt / EBITDA: -2.02 (net cash)
• Market capitalization: ¥139.97 billion
• Enterprise value: ¥121.02 billion

• Implications for investors: low financial risk from leverage, flexibility for capex/M&A or shareholder returns, and resilience in downturns due to large cash reserves.
• Valuation note: EV below market cap reflects net cash; assess operating performance and returns on capital when comparing to peers.

Mani, Inc. (7730.T) - Liquidity and Solvency

Mani, Inc. (7730.T) exhibits a notably strong liquidity and solvency profile across multiple key metrics, indicating ample short‑term resources and minimal financial risk.

• Current ratio: 8.17 - indicates very strong capacity to meet short‑term liabilities with current assets.
• Quick ratio: 6.54 - confirms liquidity quality even excluding inventories.
• Net cash position: ¥17.41 billion - a substantial cash buffer versus debt.
• Debt‑to‑equity ratio: 0.14% - extremely low financial leverage.
• Interest coverage ratio: 1,400× - exceptional ability to cover interest expenses.
• Net debt to EBITDA: -2.02 - reflects net cash (negative net debt) and strong coverage relative to earnings.
• Operating margin: 27.3% and Net profit margin: 22.05% - strong operational efficiency feeding solvency.

For broader context on the company's background, governance and business model, see: Mani, Inc.: History, Ownership, Mission, How It Works & Makes Money

Mani, Inc. (7730.T) - Valuation Analysis

• Trailing P/E: 30.15 - reflects recent earnings multiple relative to current price.
• Forward P/E: 21.17 - indicates analysts expect earnings growth or multiple compression vs. trailing.
• P/S: 4.67 and P/B: 2.58 - reasonable market valuation versus revenues and equity.
• EV/EBITDA: 16.09 - moderate enterprise-value multiple for cash operating profitability.
• EV/FCF: 1,330 - elevated, signalling very low reported free cash flow relative to enterprise value or possible timing anomalies in FCF.
• Beta: 0.19 - low volatility versus broader market, useful for defensive allocation considerations.
• Market capitalization: ≈ ¥139.97 billion; Enterprise value: ¥121.02 billion - mid-cap with a leaner EV than market cap (reflecting cash/net debt position).
• Analyst consensus price target: ¥2,230 - implies potential upside relative to the current trading level as priced into estimates.

Mani, Inc. (7730.T) Risk Factors

• Product recall impact: A voluntary product recall in China (March 2025) reduced sales by ¥1,481 million and depressed profit by ¥1,192 million, creating both near-term cash flow pressure and potential longer-term reputational/headroom risks.
• Impairment at MMG (Germany): An impairment loss of ¥1,190 million at MMG materially reduced consolidated profitability and signals asset valuation pressure in European operations.
• Regional concentration risk: Underperformance of the Dental segment in Europe increases exposure to that geography; continued weakness in European demand or reimbursement changes could further compress margins.
• Foreign exchange volatility: Fluctuations in the yen versus EUR and CNY impact reported revenues, cost of imported components, and translation of overseas earnings-amplifying earnings volatility.
• Regulatory risk: Changes in regulatory regimes (notably China) can delay approvals, force recalls, or change labeling/marketing requirements, directly affecting sales and R&D timelines.
• Competitive dynamics: Intensifying competition in medical devices and dental consumables can pressure pricing, reduce share, and require higher R&D or marketing spend to defend positions.

• Cash-flow and capital allocation implications: The combined ¥2,382 million direct hit to profit (¥1,192m recall + ¥1,190m impairment) in the period reduced operational headroom, potentially delaying discretionary investments or accelerating cost-control measures.
• Balance-sheet considerations: Impairments erode goodwill/asset cushions and may tighten covenant headroom with lenders if similar shocks recur.
• Monitoring metrics for investors:
  • Quarterly sales trend in China and Europe (volumes and ASPs)
  • Foreign exchange translation exposure and hedging disclosures
  • Regulatory status and recall remediation timelines in key markets
  • Segment profit margin trends, especially Dental in Europe

Mani, Inc. (7730.T) Growth Opportunities

Mani, Inc. (7730.T) projects a 9.4% revenue growth for fiscal year 2026, driven primarily by a recovery in the Dental segment in China and targeted expansion across Surgical and Eyeless Needle businesses. Key levers and initiatives include product-line expansion, geographic penetration, cost reductions, and enhanced R&D and partnership activity.

• Revenue growth target: +9.4% for FY2026 (company guidance).
• R&D investment planned at ¥2.8 billion for FY2026 to support new products and manufacturing improvements.
• Strategic partnership: collaboration with XYZ Corp to enhance product offerings and accelerate innovation.

Specific tactical moves supporting these drivers:

• Dental - broaden JIZAI SKUs and channel promotions in China to capture the rebound in dental procedures; anticipate this segment to be the largest contributor to the FY2026 revenue uplift.
• Surgical - invest in local regulatory approvals and targeted sales hires in the U.S.; pursue distributor partnerships in Europe and China to accelerate adoption.
• Eyeless Needle - implement process-engineering projects and automation to reduce per-unit manufacturing costs and improve margins on specialty needles.
• Partnerships & M&A - leverage the XYZ Corp alliance to co-develop complementary products and access new customer bases; consider bolt-on acquisitions to accelerate market entry where organic build-out is slow.

Financially, the planned ¥2.8 billion R&D outlay for FY2026 supports pipeline development and cost-transformation projects that underpin the 9.4% revenue target. Investors should monitor quarterly updates on:

• China Dental volume recovery metrics and JIZAI sales trends.
• Surgical segment bookings and U.S. market share progression.
• Manufacturing cost reductions and yield improvements in Eyeless Needle lines.
• Deliverables and roadmap from the XYZ Corp partnership.

For additional context on shareholder composition and recent flows, see Exploring Mani, Inc. Investor Profile: Who's Buying and Why?